Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.


Journal

Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672

Informations de publication

Date de publication:
06 2019
Historique:
received: 05 09 2018
accepted: 17 12 2018
pubmed: 21 1 2019
medline: 23 7 2020
entrez: 21 1 2019
Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC) incidence is high in The Gambia, and hepatitis B virus (HBV) infection is the main cause. People coinfected with HBV and hepatitis D virus (HDV) have an even greater risk of HCC and cirrhosis. Using a new HDV quantitative microarray antibody capture (Q-MAC) assay, we evaluated the association between HDV infection and HCC or cirrhosis among participants in The Gambia Liver Cancer Study. In this case-control study, cases had HCC (n = 312) or cirrhosis (n = 119). Controls (n = 470) had no clinical evidence of liver disease and normal serum alpha-foetoprotein. Participants were previously tested for hepatitis B surface antigen (HBsAg); we tested HBsAg+ specimens by HDV Q-MAC, western blot and RNA assays. We evaluated separate cut-offs of the Q-MAC assay for predicting anti-HDV and RNA positivity. Q-MAC correctly identified 29/29 subjects who were western blot-positive (sensitivity = 100%, specificity = 99.4%) and 16/17 who were RNA-positive (sensitivity = 94.1%, specificity = 100%). Compared to controls, cases more often had HBV monoinfection (HBsAg+/HDV RNA-; 54.1% vs 17.0%; odds ratio [OR] = 6.28; P < 0.001) or HBV-HDV coinfection (HBsAg+/HDV RNA+; 3.9% vs 0%; P < 0.001). Risk estimates (for HCC or cirrhosis) based on HDV antibody status and adjusted for covariates (demographics, alcohol, smoking, body mass index, anti-HCV and aflatoxin B1 exposure) yielded consistent results for both HBV monoinfection (adjusted OR = 8.29; 95% confidence interval = 5.74-11.98) and HBV-HDV coinfection (adjusted OR = 30.66; 95% confidence interval = 6.97-134.95). In this Gambian population, HDV Q-MAC had high sensitivity and specificity for both anti-HDV and HDV RNA. HDV infection contributed to the high risk of HCC in The Gambia.

Identifiants

pubmed: 30661282
doi: 10.1111/jvh.13065
pmc: PMC6529252
mid: NIHMS1007596
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

738-749

Subventions

Organisme : Medical Research Council
ID : MC_UP_A900_1120
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Références

Am J Trop Med Hyg. 2000 Jan;62(1):138-41
pubmed: 10761739
Am J Epidemiol. 1976 Feb;103(2):226-35
pubmed: 1251836
Hepatology. 2004 Jan;39(1):211-9
pubmed: 14752840
Int J Cancer. 2004 Jun 20;110(3):374-9
pubmed: 15095302
J Clin Microbiol. 2006 Aug;44(8):3021-4
pubmed: 16891532
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3216-23
pubmed: 18990765
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):31-40
pubmed: 20051970
J Med Virol. 2010 Aug;82(8):1371-8
pubmed: 20572078
J Natl Cancer Inst. 2012 May 16;104(10):790-2
pubmed: 22423008
Clin Infect Dis. 2013 Dec;57(12):1747-50
pubmed: 24051866
J Clin Microbiol. 2014 Feb;52(2):660-2
pubmed: 24478507
Hepatology. 2015 Jun;61(6):1870-9
pubmed: 25677884
World J Hepatol. 2015 Apr 18;7(5):777-86
pubmed: 25914778
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
J Hepatol. 2016 Sep;65(3):490-8
pubmed: 27132170
Lancet Glob Health. 2016 Aug;4(8):e559-67
pubmed: 27443781
Hepatology. 2016 Nov;64(5):1483-1494
pubmed: 27530084
Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):580-9
pubmed: 27534692
J Hepatol. 2017 Feb;66(2):297-303
pubmed: 27746337
Hepatology. 2017 Dec;66(6):1739-1749
pubmed: 27880976
J Int AIDS Soc. 2017 Feb 17;19(1):21424
pubmed: 28362065
Lancet Glob Health. 2017 Oct;5(10):e992-e1003
pubmed: 28911765
Hepatology. 2017 Dec;66(6):1716-1718
pubmed: 28961326
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Hepatology. 2018 Apr;67(4):1224-1236
pubmed: 29152762
Semin Liver Dis. 2018 Feb;38(1):66-72
pubmed: 29471567
Lancet. 2018 Mar 3;391(10123):835-836
pubmed: 29508740
J Infect Dis. 2018 May 25;217(12):1902-1906
pubmed: 29800369
J Infect Dis. 1987 May;155(5):931-5
pubmed: 3559292
Am J Public Health. 1998 Jan;88(1):15-9
pubmed: 9584027

Auteurs

Parag Mahale (P)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Peter Aka (P)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
International Health Division, Demographic and Health Surveys, ICF International, Rockville, Maryland.

Xiaohua Chen (X)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Department of Infectious Disease, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Ruth M Pfeiffer (RM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Ping Liu (P)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.

Sarah Groover (S)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Department of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma.

Maimuna Mendy (M)

International Agency for Research on Cancer, Lyon, France.

Ramou Njie (R)

International Agency for Research on Cancer, Lyon, France.
Hepatitis Unit, Disease Control & Elimination, Medical Research Council Unit The Gambia, Fajara, The Gambia.

James J Goedert (JJ)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Gregory D Kirk (GD)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Jeffrey S Glenn (JS)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Department of Microbiology and Immunology, Stanford University School of Medicine, Palo Alto, California.

Thomas R O'Brien (TR)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH